Rogier W Sanders - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Rogier W Sanders

Showing results (171-180 of 327) with videos related to

Pageof 33

Sort By:

Frontiers in Immunology|June 2, 2022

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector FunctionsAngela I Schriek, Marlies M van Haaren, Meliawati Poniman, et al.

Diagnostic Microbiology and Infectious Disease|February 26, 2022

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccinationAlba Fresco-Taboada, Marga García-Durán, Cristina Aira, et al.

Immunity|August 2, 2023

Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidatesWenhui He, Tianling Ou, Nickolas Skamangas, et al.

Immunity|November 26, 2020

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by AvidityHejun Liu, Nicholas C Wu, Meng Yuan, et al.

Journal of Virology|April 7, 2017

Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence ChangesRajesh P Ringe, Gabriel Ozorowski, Anila Yasmeen, et al.

Frontiers in Immunology|December 9, 2022

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functionsAngela I Schriek, Marlies M van Haaren, Meliawati Poniman, et al.

Science Advances|June 18, 2020

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersiteBartek Nogal, Laura E McCoy, Marit J van Gils, et al.

Proceedings of the National Academy of Sciences of the United States of America|April 7, 2025

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoproteinLaura Radić, Anna Offersgaard, Tereza Kadavá, et al.

NPJ Vaccines|March 1, 2022

High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimersIván Del Moral-Sánchez, Rebecca A Russell, Edith E Schermer, et al.

Cell Reports|August 23, 2018

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric ImmunogenWeston B Struwe, Elena Chertova, Joel D Allen, et al.

Pageof 33

Search research articles

Showing results (171-180 of 327) with videos related to

Sort By:

Pageof 33

Frontiers in Immunology|June 2, 2022

Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector FunctionsAngela I Schriek, Marlies M van Haaren, Meliawati Poniman, et al.

Diagnostic Microbiology and Infectious Disease|February 26, 2022

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccinationAlba Fresco-Taboada, Marga García-Durán, Cristina Aira, et al.

Immunity|August 2, 2023

Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidatesWenhui He, Tianling Ou, Nickolas Skamangas, et al.

Immunity|November 26, 2020

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by AvidityHejun Liu, Nicholas C Wu, Meng Yuan, et al.

Journal of Virology|April 7, 2017

Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence ChangesRajesh P Ringe, Gabriel Ozorowski, Anila Yasmeen, et al.

Frontiers in Immunology|December 9, 2022

Corrigendum: Anti-HIV-1 nanobody-IgG1 constructs with improved neutralization potency and the ability to mediate Fc effector functionsAngela I Schriek, Marlies M van Haaren, Meliawati Poniman, et al.

Science Advances|June 18, 2020

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersiteBartek Nogal, Laura E McCoy, Marit J van Gils, et al.

Proceedings of the National Academy of Sciences of the United States of America|April 7, 2025

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoproteinLaura Radić, Anna Offersgaard, Tereza Kadavá, et al.

NPJ Vaccines|March 1, 2022

High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimersIván Del Moral-Sánchez, Rebecca A Russell, Edith E Schermer, et al.

Cell Reports|August 23, 2018

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric ImmunogenWeston B Struwe, Elena Chertova, Joel D Allen, et al.

Pageof 33